Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients

被引:0
|
作者
Zhang, Xiaomin [1 ]
Yang, Jieli [1 ]
Chen, Sai [1 ]
Liu, Chang [1 ]
Wang, Zhenhua [1 ]
Ren, Hefei [1 ]
Zhou, Lin [1 ]
机构
[1] Naval Med Univ, Shanghai Changzheng Hosp, Dept Lab Med, 415 Fengyang Rd, Shanghai 200003, Peoples R China
基金
芬兰科学院; 中国国家自然科学基金;
关键词
Hypertension; Multiple myeloma; Progression-free survival; Risk stratification; BLOOD-PRESSURE; PARATHYROID-HORMONE; CANCER; RISK; CELLS; INTERLEUKIN-6; INFLAMMATION; MEDICATIONS; CALCIUM;
D O I
10.1007/s11239-022-02653-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Approximately 31% of patients diagnosed with multiple myeloma (MM) have pre-existing hypertension, but its effects on patient survival have not been investigated. We collected data from 228 newly diagnosed patients with MM and found that 71 (31.1%) had pre-existing hypertension. The impact of pre-existing hypertension on MM patients was determined by evaluating progression-free survival (PFS). Kaplan-Meier analyses revealed a significantly lower PFS in the pre-existing hypertension group than their non-hypertensive counterparts (median 22.6 vs 34.8 months, respectively). The multivariable Cox proportional hazards model showed that pre-existing hypertension was an independent risk factor for PFS reduction in MM patients. Moreover, the risk of disease progression in MM patients with pre-existing hypertension was higher than in non-hypertension comparator patients (hazard ratio 1.735, 95% confidence interval 1.261-2.387). In MM patients with pre-existing hypertension, Kaplan-Meier analyses found that those with a higher risk of hypertension had a significantly shorter PFS than those with lower risk (median 19.3 vs 25.4 months, respectively). However, multivariate Cox regression analysis showed that the risk stratification of hypertension was not an independent risk factor for poor PFS in MM patients with pre-existing hypertension. Our study demonstrates that pre-existing hypertension was significantly associated with a lower PFS in newly diagnosed MM patients.
引用
收藏
页码:542 / 549
页数:8
相关论文
共 50 条
  • [41] The presence of two light chain bands on immunofixation is associated with poor outcomes in newly diagnosed multiple myeloma patients
    Jerbi, Ameni
    Turki, Omar
    Hachicha, Hend
    Kallel Sarbeji, Faten
    Feki, Sawsan
    Mejdoub, Sabrina
    Kammoun, Khaoula
    Ben Hmida, Mohamed
    Elloumi, Moez
    Masmoudi, Hatem
    ANNALS OF HEMATOLOGY, 2023, 102 (06) : 1459 - 1466
  • [42] Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation
    Mikulski, Damian
    Koscielny, Kacper
    Nowicki, Mateusz
    Wawrzyniak, Ewa
    Kalwas, Marta
    Kowalik, Monika
    Pryt, Mateusz
    Seczkowska, Emilia
    Swiatek, Agnieszka
    Wierzbowska, Agnieszka
    Fendler, Wojciech
    LEUKEMIA & LYMPHOMA, 2023, 64 (01) : 98 - 106
  • [43] Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease
    Wang, Jing
    Shen, Na
    Shen, Xuxing
    Zhang, Run
    Jin, Yuanyuan
    Li, Jianyong
    Chen, Lijuan
    ANNALS OF MEDICINE, 2023, 55 (02)
  • [44] Recovery of policlonal immunoglobulins as a predictor factor of increased progression-free survival and overall survival in patients with multiple myeloma ineligible for ASCT
    Davila, Julio
    Gonzalez-Calle, Veronica
    Puig, Noemi
    Barez, Abelardo
    Escalante, Fernando
    Rosa, Lopez
    Maria Alonso, Jose
    Aguilar, Carlos
    Garcia-Mateo, Aranzazu
    Contreras, Teresa
    Labrador, Jorge
    Aguilera, Carmen
    Garcia de Coca, Alfonso
    Hernandez, Roberto
    Mateos, Maria-Victoria
    Ocio, Enrique M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E176 - E177
  • [45] Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients
    Geng, Chuanying
    Yang, Guangzhong
    Wang, Huijuan
    Wu, Yin
    Leng, Yun
    Zhou, Huixing
    Zhang, Zhiyao
    Jian, Yuan
    Chen, Wenming
    LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 883 - 890
  • [46] The presence of two light chain bands on immunofixation is associated with poor outcomes in newly diagnosed multiple myeloma patients
    Ameni Jerbi
    Omar Turki
    Hend Hachicha
    Faten Kallel Sarbeji
    Sawsan Feki
    Sabrina Mejdoub
    Khaoula Kammoun
    Mohamed Ben Hmida
    Moez Elloumi
    Hatem Masmoudi
    Annals of Hematology, 2023, 102 : 1459 - 1466
  • [47] Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
    van de Velde, Helgi J. K.
    Liu, Xiangyang
    Chen, Gang
    Cakana, Andrew
    Deraedt, William
    Bayssas, Martine
    HAEMATOLOGICA, 2007, 92 (10) : 1399 - 1406
  • [48] Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma
    Meddour, Yanis
    Rahali, Momahed C.
    Belakehal, Salah E.
    Ardjoun, Fatma Z.
    Chaib, Samia
    Djidjik, Reda
    CLINICAL LABORATORY, 2018, 64 (04) : 551 - 558
  • [49] The Value of Minimal Residual Disease as a Progression-Free Survival Predictor After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients
    Solovev, Maxim
    Mendeleeva, Larisa
    Firsova, Maiia
    Julhakyan, Hunan
    Galtseva, Irina
    Davydova, Julia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S324 - S324
  • [50] Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma
    Ghosh, Nilanjan
    Ye, Xiaobu
    Ferguson, Anna
    Huff, Carol Ann
    Borrello, Ivan
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (05) : 593 - 599